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Highlights 
 The novel adamantanyl-derived indole APICA induces cannabimimetic effects in mice. 
 APICA induced hypothermia, analgesia, and catalepsy through CB1 receptor activation.  
 Single exposure to APICA dose-dependently elicits memory impairment in mice. 
 APICA can be included in the Italian Consolidated Test of Drugs (D.P.R. 309/90). 
Highlights (for review)
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BEHAVIOURAL AND PHARMACOLOGICAL CHARACTERIZATION OF A NOVEL 
CANNABINOMIMETIC ADAMANTANE-DERIVED INDOLE, APICA, AND CONSIDERATIONS ON THE 
POSSIBLE MISUSE AS A PSYCHOTROPIC SPICE ABUSE, IN C57BL/6J MICE 
 
 
Abstract 
 
The novel adamantane derivative APICA (N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide) was recently 
identified as a cannabinomimetic indole of abuse. Despite its novel structure, APICA recalls cannabinomimetic indoles, 
such as representative member JWH-018.  
In present study, the effects of APICA (0 - 1 - 3 mg/Kg, i.p.) were tested in C57BL/6J mice, in the Tetrad task which 
includes the assessment of: body temperature; locomotor activity and behavioural reactivity; nociception; motor 
coordination; declarative memory. Furthermore, pre-treatment with the CB1 antagonist AM251 (3 mg/Kg, i.p.) or the 
CB2 antagonist AM630 (3 mg/Kg, i.p.) was carried out to characterize APICA activity. 
Our results show that APICA was able to dose-dependently decrease locomotor activity and behavioural reactivity in 
the open field, whereas only the highest dose was able to induce hypothermia, analgesia, motor incoordination and 
recognition memory impairment, with respect to vehicle (p<0.01; p<0.001).  
The pretreatment with the CB1 antagonist AM251 elicited an increase in body temperature, total distance travelled in 
the open field, latency to fall down in the Rotarod, and a decrease in tail flick latency (p<0.05; p<0.01). On the other 
hand, pretreatment with AM630 did not induced significant differences on APICA effects. 
This study supports preliminary reports on APICA cannabinomimetic properties, extending its detrimental effects on 
cognitive function. Moreover, these properties can be attributed to the CB1 receptor activity, indicating APICA as a 
selective CB1 receptor agonist. 
 
Keywords 
 
Synthetic Cannabinoid, CB1 Agonist, New Psychotropic Substances, APICA 
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Introduction 
 
The alarming issue of the emergence of New Psychotropic Substances (NPS) represents one of current challenges in 
toxicology. Among them, synthetic cannabinoids (SC) are the most widespread in U.S.A. and Europe since 2000: they 
share similar pharmacological properties as cannabis sativa’s derivatives, D9-THC, cannabinol and cannabidiol, and 
endocannabinoids, anandamide and 2 arachidonoylglycerol. These compounds act on specific receptors: CB 1 
receptors,are localized in the central nervous system and their activation modulate many superior functions as learning 
and memory,  mood, stress reactivity and locomotor activity. CB 2 receptors are located peripherally in immune cells, 
spleen and thymus and are involved in anti-inflammatory and cytotoxic mechanisms. Despite the similarities SC are not 
easily recognizable. Indeed, these molecules are constantly considered to escape the current controls and legal 
limitations and to strengthen the psychotropic effects. 
They can be identified by gas chromatography in association with mass spectrometry and are involved in many forensic 
issue as safety at work, road safety, work tasks at risk but also in many cases of hospital admissions for acute 
intoxication  [31 – 32]. 
In front of these considerations Europe and Italy have actuated enforcement and prevention of NPS and SC use [34]. 
However, the ongoing changes in the active cannabinoids contained in legal highs still represent a persisting difficulty  
for forensic and law enforcement personnel [1-3]. In this regard, the structure of the adamantanyl derivative N-
(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide) (APICA) recalls JWH-018, the representative member of 
cannabinomimetic indoles. In 2012, APICA was detected in products obtained by the National Institute of Health 
Sciences in Japan and recently its synthesis and preliminar pharmacological characterization have been published [4]. 
The emerging spreading of synthetic cannabinoids highlights the need for further evaluation of the in vivo properties 
and a further pharmacological characterization of indole-derived cannabinoids.  
Therefore, the purpose of the present paper was to determine whether the indole-derived compound APICA produces 
cannabinomimetic behavioural activity in mice, by using the tetrad task, which is a widely used assay to investigate in 
vivo effects  of THC and other cannabinoids, including antinociception, catalepsy, hypothermia, and hypomobility [5]. 
Other measures of cannabinoid activity, including effects on anxiety-like behaviour and on declarative memory were 
also assessed. The further goal of this research was to characterize the pharmacological profile of APICA, by using CB1 
and CB2 receptor antagonist. 
  
 
Materials and Methods 
 
Animals and housing conditions 
25 Female C57BL/6J mice (6 weeks), obtained from Charles River (Italy) were housed in groups of five in standard 
cages (Tecniplast, Italy) and maintained in a temperature- (22 ± 2 °C) and humidity- (55 ± 5 %) controlled room, with 
ad libitum access to water and food (Mucedola, Italy). The colony was maintained on 12 h light/dark cycle (light on 
from 08:00 to 20:00) and mice were gently handled for 3 min per day for a week before the experimental procedures. 
On the test days, animals were brought into the laboratory 60 minutes before the experimental sessions to acclimatize. 
The experiments were carried out in a sound isolated room between 9:00 and 14:00. A two-week interval was given 
between the experiments. Animal performance was recorded on videotape and monitored in an adjacent room. To 
ensure that mouse’s behaviour was not affected by the detection of another mouse’s scent, all the devices were 
thoroughly cleaned 10 min before the animal's entry into the cages. All the experiments were conducted in accordance 
with the regulations of the Committee for the Protection and Use of Animals of the University of Palermo, in 
accordance with current Italian legislation on animal experimentation (D.L. 116/92) and the European directives 
(2010/63/EU) on care and use of laboratory animals. Every effort was made to minimize the number of animals used 
and their surrow. 
 
Drugs 
The syntetic indole-derived APICA (N-1-adamantyl-1-pentyl-3H-indole-3-carboxamide) was synthesized by the
 
Department of Pharmaceutical Sciences of the University of Milan. 
 
N-(adamantan-1-yl)-1-pentyl-1H-indole-3-carboxamide 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC, 762 mg, 3.99 mmol), hydroxybenzotriazole (HOBt, 539 mg, 
3.99 mmol) and N,N-Diisopropylethylamine (DIPEA, 1.39 mL, 7.99 mmol) were added to a solution of 1-pentylindole-
3-carboxylic acid (840 mg, 3.63 mmol) diluted in DMF (11 mL). After 0.5 h at room temperature 1-aminoadamantane 
(549 mg, 3.63 mmol) was added to this solution. Stirring was continued for 2 h at room temperature and at the end the 
solvent was concentrated. The resultant residue was dissolved in dichloromethane (20 mL) and washed twice with water 
(10 mL). The organic phase was separated, dried (Na2S04) and concentrated. The resultant residue was treated with 
ethanol to quantitatively precipitate the product as white solid (mp 141 °C). Melting point was determined by DSC 
analysis and corresponded to the peak maximum. 
1
H NMR spectra was recorded operating at 300 MHz and 
13
C NMR at 
75 MHz. Chemical shifts are reported in ppm relative to residual solvent (CHCl3) as internal standard. Signal 
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multiplicity is designed according to the following abbreviations: s singlet, d doublet, t triplet, m multiplet, br s broad 
singlet. Coupling constants are reported in Hertz (Hz). 
1
H-NMR (300 MHz, CDCl3):  7.87 (1H, d, J = 7.5 Hz), 7.63 (1H, s), 7.38 (1H, d, J = 8 Hz,), 7.25-7.20 (2H, m) 5.7 
(1H, br s, NH) 4.17 (2H, t, J = 7.3 Hz), 2.20-2.18 (9H, br s), 1.82 (2H, m), 1.78 (6H, br s) 1.40-1.22 (4H, m), 0.84 (3H, 
t, J = 7.0 Hz) 
13
C-NMR (75 MHz):  164.5, 136.7, 131.7, 124.8, 122.2, 121.8, 120.1, 112.0, 110.1, 52.0, 46.3, 42.2, 36.2, 30.0, 29.3, 
22.1, 14.0. 
EIMS: m/z [ion] (rel. int.%) 364 [M]
+
 (50), 347 (29), 307 (60), 264 (18), 214 (100), 144 (25).(Fig. 1). 
The selective CB1 receptor antagonist AM251 and the selective CB2-receptor antagonist AM630 were obtained from 
Sigma Aldrich, Italy.  
Drugs were initially dissolved in 3% ethanol, then 3% Tween 20 was added, and then 94% physiological saline was 
added [4]. All drugs were injected intraperitoneally (i.p.) at a volume of 1 mL/kg. 
APICA and vehicle were administered 30 min before testing, while pre-treatment with the antagonists AM251 and 
AM630 occurred 30 min before APICA or vehicle administration.  
In Experiment 1 (tetrad task), APICA was administered at 1 and 3 mg/kg..  
Mice in Experiment 2 were pretreated with vehicle, AM251 at 3.0 mg/kg or AM630 at 3.0 mg/kg. The doses of the 
CB1- and CB2- receptor antagonists were based on previous research on reversal of tetrad effects induced by other CB1 
agonists [8, 9]. 
 
Tetrad-task 
 
Open field test 
Locomotor activity and behavioural reactivity in a novel environment were measured in an open field with an automatic 
video-tracking system, Any Maze (Ugo Basile, Italy), in a mean light intensity (100 lx) illuminated chamber. The 
apparatus is a Plexiglas square box, 44 cm long, 44 cm wide, and 20 cm high. The system produces a qualitative 
mapping of the motor patterns, measuring different parameters simultaneously: total distance travelled (TDT), as a 
measure of locomotor activity, number of transitions (NCT) from peripheral to central squares of the arena, and amount 
of time spent on the central areas (TSC) as measures of explorative behaviour. Each experimental session lasted 5 min. 
The animal motor patterns were recorded 1 min after the mice were placed in the box, and displayed on a PC. 
 
Body temperature 
Body temperature was measured using a rectal probe in conscious mice and was monitored by a thermalert monitoring 
thermometer. Temperature was the mean of 3 measurements every 20 sec, over 1 min. for each dosage. Body 
temperature measurement was repeated at 1h, 2h and 3h. 
 
Rotarod test 
Motor coordination was assessed by using a Rota-rod unit (Ugo Basile, Italy). Animals were required to walk against a 
rotating drum at increasing speed from 4 revolutions per min (rpm) to 40 rpm [8]. The latency to fall off the rotating 
drum was recorded (seconds). No cut-off latency was employed in the Rota-rod test, to ensure that the detection of 
subthreshold motor coordination would not be masked [9]. Rota-rod training took place on the two days prior to the test 
day. Animals were given a minimum of three practice trials on both training days. Practice trials terminated when the 
animal fell off the rotating drum. Training trials in which the animal failed to remain on the rotating drum for a 
minimum of 10 sec were re-run. On the test day, reliability testing was performed. Animals that did not remain on the 
rotating drum for 30 sec in two separate trials failed to meet the criteria, and were dropped from the experiment.  Rota-
rod latency to fall was measured after 45 min from the drug injection, and reported as the mean of two trials.  
 
Hot-water immersion tail-flick test 
Nociception was explored by measuring tail-flick latencies in the hot-water immersion tail flick test [10]. 
Briefly, two centimeters of the tail were immersed in a water bath apparatus  (Instruments srl, Bernareggio, MI, Italy) 
maintained at 52±0.5 °C. Latency to response was determined by a vigorous tail flick. A cut-off time of 10 s was 
imposed to minimize tissue damage.  
 
Novel Object recognition task 
This test was carried out in the open field Plexiglas square box, in a mean light intensity (100 lx) illuminated chamber. 
APICA at 3 mg/kg, i.p was administered 30 min before the experiment: mice were subjected to a 5-min training session 
when they were presented two identical, non-toxic objects (i.e. two metal cans) placed against a wall in the open field 
arena. To prevent coercion to explore the objects, mice were released against the opposite wall with the back to the 
objects. The time spent on exploring each object was recorded using ANY MAZE Video Tracking System, (Ugo Basile, 
Italy); a 2-cm
2
 area surrounding the object was defined such that nose entries were recorded as time exploring the 
object. After the training session, animals were placed in their home cage for a 24 h retention interval. Then, they were 
returned to the arena containing two objects: one was identical to the familiar one but previously unused (to prevent 
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olfactory cues and the necessity to wash objects during experimentation), the other was a novel object (metal, glass or 
hard plastic items). Time spent on exploring each object was recorded along 5-min session. Objects were randomized 
and counterbalanced across animals. The objects and arena were thoroughly cleaned at the end of each experimental 
session. The recognition index (RI), which is the time spent on investigating the novel object, divided by the total 
amount of exploration time of the novel and familiar objects, [RI = TN/(TN + TF)], is a measure of novel object 
recognition and the main index of retention [11, 12]. If RI percentage is higher than 50%, it indicates more time spent 
on enquiring into the novel object, whereas less than 50% indicates that time was prevailingly spent on exploring the 
familiar object, and 50% indicates a null preference. 
 
 
Experiment 1 - Effects of APICA on the tetrad task 
Following the administration of vehicle, 1 or 3 mg/kg APICA ,i.p., animals (n = 5 per group) were tested for locomotor 
activity, and then for body temperature, motor coordination, and analgesia. Doses listed above were administered i.p. 30 
min prior to the start of the locomotor activity assay. 
 
Experiment 2 - Duration of the effects of APICA on thermoregulation, nociception and motor coordination  
The duration of the effects of APICA (3 mg/kg, i.p n=5 per group).) was assessed on body temperature, motor 
coordination, and then analgesia, monitoring the animal parameters (along three consecutive time points (T1: 1h; T2: 
2h; T3: 3h). 
 
Experiment 3 - Pharmacological characterization of APICA effects in the tetrad task 
The assessment of the pharmacological profile of APICA was carried out by pre-treating a separate groups of mice (n = 
5 per group) with the CB1 receptor antagonist AM251   or CB2 receptor antagonist AM630, 20 min prior to APICA 
administration. Each animal was tested for locomotor activity in the Open field test, as well as for thermoregulation, 
nociception in the Tail-flick test and motor coordination in the Rotarod test. 
 
Experiment 4 - Effects of APICA on recognition memory in the novel object recognition test 
After a two-week washout, the effect of APICA (1 - 3 mg/kg, i.p., n = 5 per group) on declarative memory was assessed 
by using the novel object recognition test. The drug was administered 30 min before the presentation of the novel 
object. 
 
Data analysis 
 
Data were analysed by using GraphPad Prism v. 6.1 (La Jolla, CA). One-way analysis of variance (ANOVA) was 
performed for assessing the main effect of treatment; two-way ANOVA for repeated measures was employed for 
assessing the effects of treatment, considered as the between-subject factor, and time, as the within-subject factor. 
Bonferroni post-hoc test was used, when necessary. Statistical difference was considered for p<0.05. 
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Results 
 
Experiment 1- Effects of APICA on the tetrad task 
 
Open field test 
The animals were subjected to the open field test 30 minutes after the administration of APICA (1 - 3 mg/kg) to 
evaluate the effect of different doses on locomotor activity and behavioral reactivity. 
The results of one-way ANOVA on total distance travelled (TDT) show a significant effect of treatment (F: 2, 12 = 
14.78; p = 0.0006). Administration of APICA reduced locomotor activity in a dose-dependent manner. In particular, the 
Bonferroni post hoc test highlights,  and to a greater extent for the dose of a significant reduction in TDT at 1 mg / kg (t 
= 3.194, p <0.05), and a  further decrease at  3 mg / kg (t = 5.407, p <0.001),  with respect to controls (Fig. 2A). 
Administration of APICA also reduced behavioral reactivity exploration of the central area of open field. In fact, the 
analysis of data on the number of transitions in the center of the arena (NCT) shows a significant effect of treatment (F 
(2, 12) = 10.07; p = 0.0027). In detail, the Bonferroni post hoc test indicates a significant reduction of the NCT at 1 
mg/kg (t = 3.704; p <0.01) and at 3 mg/kg (t = 4.048; p <0.01), compared to vehicle (Fig. 2B). Consistently, we 
observed a significant effect of treatment on time spent in the center of the arena (TSC): (F (2, 12) = 8,986; p = 0.0041), 
in a dose-dependent manner (1 mg / kg: t = 3.591; p <0.05; 3 mg / kg t = 3.747; p <0.01), compared to vehicle (Fig. 
2C). 
 
 
Body temperature 
The body temperature of the animals was measured at 35 minutes after APICA injection  (1 - 3 mg / kg) to evaluate the 
effect of the different doses used on thermoregulation. 
The one-way ANOVA shows a significant effect of treatment (F (2, 12) = 13:32; p = 0.0009). In detail, the post hoc 
analysis shows a significant reduction in body temperature in the group treated with 3 mg/kg with respect to vehicle (t = 
4.600, P <0.01) and compared to the group treated with 1 mg/kg (t = 4,328; p <0.01) (Fig. 2D). 
 
Hot water- tail flick test 
The animals were subjected to the tail flick test 40 minutes after the administration of APICA (1 - 3 mg / kg) to evaluate 
the effect of different doses on nociception. 
Statistical analysis performed on tail flick latency shows a significant effect of treatment (F (2, 12) = 21.71; p = 0.0001). 
The administration of APICA had an antinociceptive effect. In particular, the Bonferroni post hoc test indicates a  
significant increase in tail flick latency in the group treated with 3 mg / kg compared to vehicle (t = 6.290, P <0.001) 
and the group treated with 1 mg / kg (t = 4.848 ; p <0.01) (Fig. 2E). 
 
Rotarod test 
The animals were subjected to the Rotarod test 45 minutes after the administration of APICA (0 - 1 - 3 mg / kg) to 
evaluate the effect of different doses on the motor coordination. 
The one-way ANOVA shows a significant effect of treatment on latency to fall (F (2, 12) = 9,971; p = 0.0028). The 
administration of APICA reduced motor coordination of the animals. In particular, the Bonferroni post hoc test shows a 
reduction of down time in the group treated with 3 mg/kg compared to vehicle (t = 4.268, P <0.01) and compared to the 
group treated with 1 mg / kg (t = 3.273; p <0.05) (Fig. 2F). 
 
 
Experiment 2 - Duration of the effects of APICA on thermoregulation, nociception and motor coordination 
 
Body temperature 
In order to assess the duration of APICA activity, thermoregulation, nociception and motor coordination were 
sequentially evaluated every 60 minutes (T1, T2, T3) from APICA injection at the dose of 3 mg/kg. 
The results of a two-way ANOVA for repeated measures, carried out considering  "treatment" as between subject factor 
and "time" as within subject factor, show a significant effect of time (F (2, 16) = 11.91; p = 0.0007), treatment (F (1, 8) 
= 8,871, p = 0.0176) and their interaction (F (2, 16) = 10:38; p = 0.0013) on  body temperature. The administration of 
APICA had a maximum hypothermic effect at T1, yet at T2 but not T3. In detail, the Bonferroni post hoc test indicates 
a significant reduction in body temperature in the APICA group with respect to vehicle, at T1 (t = 4.355, p = 0.0006) 
and T2 (t = 2.882, p = 0.0246) (Fig. 3A). 
 
Hot water - tail flick test 
The results of two-way ANOVA for repeated measures on data from the tail flick test showed a significant treatment 
effect (F (1, 6) = 25.23; p = 0.0024). The administration of APICA had a maximum antinociceptive effect at T1, yet at 
T2 and T3. In particular, the Bonferroni post hoc test shows a statistically significant increase in tail flick latency at T1 
(t = 4.365, p = 0.0011), T2 (t = 4,762, p = 0.0005) and T3 (t = 3.163, p = 0.0162), with respect to vehicle (Fig. 3B). 
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Rotarod test 
The results of two-way ANOVA for repeated measures on  descent latency in the Rotarod test show a significant effect 
of time (F (2, 12) = 7.821; p = 0.0067) and treatment (F (1, 6) = 17:28; p = 0.006). Also in this case, the impairment of  
motor coordination determined by the administration of APICA was no longer present at T3. In particular, the 
Bonferroni post hoc shows a significant decrease in descent latency at T1 (t = 4.486, p = 0.0009) and T2 (t = 2.54; p = 
0.0392) in the group treated with APICA respect to the vehicle (Fig. 3C). 
 
Experiment 3 - Pharmacological characterization of APICA effects in the tetrad task 
 
In order to evaluate the pharmacological activity of APICA, animals were pre-treated with the selective CB1 antagonist 
AM251 or with the CB2 receptor antagonist AM630, before receiving the administration of APICA, and tested for 
locomotor activity, body temperature, nociception and motor coordination. 
 
Open Field Test 
The one-way ANOVA on the data of TDT in the open field test shows a significant effect of treatment (F (3, 16) = 
4.211; p = 0.0225). Specifically, the pre-treatment with AM251 resulted in a significant increase in the TDT with 
respect to the group treated with APICA (t = 3.365, p <0.05), while the pre-administration of AM630  had no effect 
compared to APICA (Fig. 4A). No differences were observed with respect to vehicle-treated mice. 
 
Body Temperature 
In addition, the statistical analysis on the data of body temperature shows a significant effect of treatment (F (3, 16) = 
43.30; p <0.001). AM251 resulted in a significant increase in body temperature compared to the group treated with 
APICA (t = 6.803, p <0.001), while the pre-administration of AM630 has had no effect compared to APICA (Fig. 4B). 
no differences in temperature were observed with respect to vehicle. 
 
Hot water - tail flick test 
Consistently, the one-way ANOVA performed on data from tail flick latency shows a significant effect of treatment (F 
(3, 16) = 12.38; p = 0.0002). In particular, the pre-treatment with AM251 resulted in a significant reduction in the tail 
flick latency compared to the group treated with APICA (t = 3.170, p <0.05), while AM630 did not exert  significant 
effects compared to APICA (Fig. 4C). No differences were observed with respect to vehicle-treated mice. 
  
Rotarod test 
The one-way ANOVA on data of descent latency in the Rotarod test shows a significant effect of treatment (F (3, 16) = 
21.03; p <0.001). In particular, the pre-treatment with AM251 resulted in a significant reduction in descent latency 
compared to the group treated with APICA (t = 4.383, p <0.01), while AM630 had no statistically significant effect 
compared to APICA (Fig.4D). No differences were observed with respect to vehicle-treated mice. 
 
 
Experiment 4 - Effect of APICA on declarative memory in the novel object recognition test 
 
The animals were subjected to the novel object recognition test, 30 minutes after administration of APICA (1 - 3 
mg/kg), to evaluate the effect of different doses on declarative memory, assessed by the Recognition Index (RI)%. The 
results of one-way ANOVA show a significant effect of treatment (F (2, 12) = 8,959; p = 0.0042). Administration of 
APICA resulted in a dose-dependent impairment of declarative memory: the post hoc analysis shows a statistically 
significant reduction of RI% both for the dose of 1 mg / kg (t = 2.783, p <0.05) and for 3 mg / kg (t = 4.152; p <0.01) 
compared with vehicle (Fig. 5). 
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Discussion 
 
The purpose of the present paper was to investigate the cannabinomimetic properties of a novel adamantly-indole-
derived compound, APICA, in a battery of tests known as Tetrad task, which is highly sensitive to the effects of 
psychoactive cannabinoids [5]. It includes the assessment of locomotor activity, nociception (tail flick assay), motor 
coordination and body temperature. Our results show that, when administered to mice at the dose of 1 and 3 mg/kg, 
APICA showed behavioural effects typical of cannabinoid agonists, such as suppression of spontaneous locomotion, 
antinociception, hypothermia, and loss of motor coordination. These effects seemed to be played by the interaction with 
CB1 receptors. Moreover APICA was also able to disrupt declarative memory in the Novel object recognition task.  
APICA administration dose-dependently decreased total distance traveled in the open field test, This result is consistent 
with preliminary evaluation of APICA cannabinomimetic profile, which showed that APICA dose-dependently induced 
hypothermia and reduced heart rate at the maximal dose of 10 mg/kg, a similar potency as Δ9-THC, but lower than 
JWH-018, the representative member of cannabinomimetic indoles [4].  
Since CB1 agonists have been shown to exert anxiogenic effect [13], we also evaluated APICA activity on behavioural 
reactivity in the open field. Our results show that APICA strongly decreased the time spent in the center of the arena, as 
well as the number of transitions in the central area, and this observation is consistent with an overall reduction of 
locomotor activity and exploration. However, a cannabinoid-like modulation of emotionality cannot be ruled out. 
Indeed, it has been clearly demonstrated that cannabinoid signaling is involved in the control of anxiety, albeit it has 
been difficult to define the exact role of this signaling. In particular, both anxiolytic- and anxiogenic-like effects have 
been reported by using cannabinoid receptor agonists at low and high doses, respectively [14], and also by CB1 receptor 
antagonists [15, 16]. These opposite observations might be explained by the distribution of CB1 receptors in the brain. 
Rey et al. [13] showed a biphasic effects of the synthetic CB1 cannabinoid receptor agonist CP-55,940, demonstrating 
that the anxiogenic effect exerted by the high doses was mediated via the CB1 receptor activation on the GABAergic 
terminals. Indeed, the broad distribution of CB1 receptors in the central nervous system [17], together with its 
modulatory role on neurotransmission [18], account for the controversial activity of cannabinoids on anxiety 
modulation. Our results are consistent with data from McLaughlin et al. [6] showing that another adamantyl 
cannabinoid agonist, AM 411, reduced both outside (thigmotaxic movements) and inside line crossings in the open field 
task, indicating an anxiogenic profile for adamantyl-derived compounds. Our finding represents a preliminary report on 
APICA-induced reduction of behavioural reactivity and explorative behaviour; a further characterization of APICA 
effects on anxiety-like behaviour would benefit from more specific behavioural paradigms. 
In order to gather information on the pharmacokinetic profile of APICA, thermoregulation, motor coordination and 
nociception parameters were sequentially evaluated at 30 min, 1h, 2h and 3 h from APICA injection. Our data show that 
APICA induced reduction of body temperature, suppression of motor coordination, and nociception in a dose dependent 
manner. The hypothermic effect and motor incoordination lasted for 1 h, while the analgesic effect was observed up to 
2h from the first measurement. It is worth noting that, in contrast with previous findings in rats [4], in our study APICA 
effects were reversible at 3 h post-administration. Because other pharmacological compounds  (i.e. dopamine D2 
antagonists) produce cannabinoid-like effects on the tetrad task [19], the further aim of this study was to 
pharmacologically characterize the effects of APICA on the behavioural patterns examined. Indeed APICA activity was 
verified by reversing its behavioural effects by a CB1-selective antagonist/inverse agonist such as AM 251 [20] and a 
CB2-selective antagonist AM 630 [21]. Our results show that APICA effects on the Tetrad task depend on CB1 receptor 
activation: indeed the pretreatment with the AM251 was able to revert the effect of APICA on locomotor activity, body 
temperature, nociception and motor coordination, and no significant differences were observed with respect to control 
group. Banister and colleagues [4] showed that APICA is a full cannabinoid agonist with comparable affinity for both 
CB1 and CB2 cannabinoid receptors in vitro, and that CB2 receptors may modulate pain in inflammatory [23] and non-
inflammatory states [24], via local peripheral mechanisms. Over the last decade, accumulating evidence has shown that 
CB2 receptors are also widely present in both microglia and neurons [25-27]. However, when AM630 was administered 
before APICA, the significant decrease in locomotor activity in the open field, body temperature and motor 
coordination in the Rotarod, together with the increased tail flick latency, were not modified.  Our data rules out the 
involvement of CB2 receptor in APICA effects on the tetrad task, suggesting that they are centrally- and CB1-mediated. 
Endogenous and exogenous CB receptor agonists modulate learning and memory mainly through the activation of CB1 
receptor [28, 29]. Thus, the final aim of this study was the evaluation of APICA effects on declarative memory in the 
novel object recognition test. Our results show that the administration of APICA before the presentation of the novel 
object was able to decrease the recognition index in a dose dependent manner. This is the first report of a detrimental 
effect on memory processes in the rat, and since APICA was detected in 2012 in Japan as new designer drug [30] its 
detrimental effect on declarative memory raises relevant health concerns about its widespread illicit recreational use. 
Future studies should assess the effects of repeated administration of this compound, as well as the extent of recovery. 
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Conclusions 
 
In the present study, we report that systemic exposure to the novel adamantanyl-derived indole, APICA in mice 
produces a large spectrum of effects that is typically indicative of cannabinomimetic activity. In particular the tetrad 
assay reveals that it shares some physical properties of THC and other cannabinoids, including (1) antinociception, (2) 
incoordination, (3) hypothermia, and (4) hypomobility [5]. The observations that AM251, but not AM630, antagonizes 
APICA-induced behavioural signs indicate a CB1 receptor-related mechanism of action. Moreover, we also report that a 
single exposure to APICA dose-dependently elicits memory impairment in mice, raising further concerns about its 
recreational use.  
APICA is used as drug of abuse for its psychotropic effects. In Italy, the above-mentioned law (L.D. 122 on may 16, 
2011), includes JWH 018, JWH 122 and JWH 250 in the Consolidated Test of Drugs (D.P.R. 309/90 – table A).   We 
assume that according to the structural analogies between APICA and JWH 018, APICA should be recognized as an 
illicit compound.  
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Fig. 1. APICA synthesis. Reagents and conditions: (a) EDAC, HOBt, DIPEA, DMF, rt, 2.5 h. 
 
Fig. 2. Effect of APICA on the tetrad task. APICA decreased locomotor activity (A) and behavioural reactivity (B, 
C); APICA induced hypothermia (D); antinociception (E) and motor incoordination (F). * p <0.05, ** p <0.01, *** p 
<0.001 compared with vehicle. ° p <0.05; °° p <0.01 compared with the dose of 1 mg / kg. Every value represents 
the mean ± SD of n=5 mice. 
 
Fig. 3. Duration of the effects of APICA on body temperature (A), nociception (B) and motor incoordination (C). * 
p <0.05, **p < 0.01, *** p <0.001 compared with vehicle. Every value represents the mean ± SD of n=5 mice. 
 
Fig. 4. Effect of the pre-treatment with the CB1 antagonist AM251 and the CB2 antagonist AM630 on APICA-
induced hypolocomotion (A), hypothermia (B), analgesia (C) and motor incoordination (D). *** p <0.001 
compared with vehicle; ° p <0.05, °° p <0.01, °°° p <0.001 compared with APICA. Every value represents the mean 
± SD of n=5 mice. 
 
Fig. 5. Effect of the administration of APICA on declarative memory. * p <0.05, ** p <0.01  compared with vehicle. 
Every value represents the mean ± SD of n=5 mice. 
 
Legend
